Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Rhea-AI Summary

Abivax (ABVX) has announced the filing of its Universal Registration Document with the French Financial Market Authorities (AMF) and its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.

The Universal Registration Document contains the 2024 annual financial report, management report including corporate governance report, and statutory auditors' reports. These documents will be accessible on Abivax's website, AMF, and SEC's EDGAR system.

Abivax is a clinical-stage biotech company developing treatments for chronic inflammatory diseases. Their lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.

Positive

• Lead drug candidate obefazimod advancing in Phase 3 trials for ulcerative colitis

Negative

• None.

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.

The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

FAQ

What regulatory filings did Abivax (ABVX) submit in March 2025?

Abivax filed its Universal Registration Document with the French AMF and Annual Report (20-F) with the U.S. SEC on March 24, 2025.

What is the current development stage of Abivax's (ABVX) lead drug candidate obefazimod?

Obefazimod (ABX464) is in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.

Where can investors access Abivax's (ABVX) 2024 annual financial report?

The 2024 annual financial report is available on Abivax's website, AMF website, and SEC's EDGAR system.

What therapeutic area does Abivax (ABVX) focus on?

Abivax focuses on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms.